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Successful Versus Failed Adaptation to High-Fat
Diet–Induced Insulin Resistance
The Role of IAPP-Induced -Cell Endoplasmic Reticulum
Stress
Aleksey V. Matveyenko, Tatyana Gurlo, Marie Daval, Alexandra E. Butler, and Peter C. Butler
OBJECTIVE—Obesity is a known risk factor for type 2 diabe-
tes. However, most obese individuals do not develop diabetes
because they adapt to insulin resistance by increasing -cell
mass and insulin secretion. Islet pathology in type 2 diabetes is
characterized by -cell loss, islet amyloid derived from islet
amyloid polypeptide (IAPP), and increased -cell apoptosis
characterized by endoplasmic reticulum (ER) stress. We hypoth-
esized that IAPP-induced ER stress distinguishes successful
versus unsuccessful islet adaptation to insulin resistance.
RESEARCH DESIGN AND METHODS—To address this, we
fed wild-type (WT) and human IAPP transgenic (HIP) rats either
10 weeks of regular chow or a high-fat diet and prospectively
examined the relations among -cell mass and turnover, -cell
ER stress, insulin secretion, and insulin sensitivity.
RESULTS—A high-fat diet led to comparable insulin resistance
in WT and HIP rats. WT rats compensated with increased insulin
secretion and -cell mass. In HIP rats, in contrast, neither -cell
function nor mass compensated for the increased insulin de-
mand, leading to diabetes. The failure to increase -cell mass in
HIP rats was the result of ER stress–induced -cell apoptosis that
increased in proportion to diet-induced insulin resistance.
CONCLUSIONS—IAPP-induced ER stress distinguishes the
successful versus unsuccessful islet adaptation to a high-fat diet
in rats. These studies are consistent with the hypothesis that
IAPP oligomers contribute to increased -cell apoptosis and
-cell failure in humans with type 2 diabetes. Diabetes 58:
906–916, 2009
I
nsulin resistance, most often attributed to high-
caloric food intake and consequent obesity (1), is a
well-characterized risk factor for type 2 diabetes
(2,3). However, most obese individuals (80%) do
not develop diabetes (4) because they are able to compen-
sate for insulin resistance by an adaptive increase in
insulin secretion (5,6). Type 2 diabetes develops as a result
of a failure to adequately increase insulin secretion to
meet demands of insulin resistance (5,7,8). Consistent
with this, genomewide studies imply that the genetic
variance that underlies predisposition to type 2 diabetes is
manifest in pancreatic -cells (9–11). By implication, there
is a subset of individuals in the general population at risk
of developing type 2 diabetes if subject to insulin resis-
tance. These observations raise the question, what under-
lies the failure of -cell adaptation to insulin resistance in
those predisposed to type 2 diabetes?
Some insights arise from the pathology of the islet in
type 2 diabetes. There is a 60% deﬁcit in -cells in
individuals who are obese with type 2 diabetes compared
with those comparably obese but nondiabetic (12,13). The
islet in type 2 diabetes is also characterized by islet
amyloid derived from islet amyloid polypeptide (IAPP)
(12). High expression rates of human IAPP in some rodent
models recapitulate this islet pathology and lead to diabe-
tes (14–17). In the HIP rat (Sprague-Dawley rats trans-
genic for human IAPP), there is a gradual decline in -cell
mass leading to impaired fasting glucose at 5 months of
age and diabetes by 10 months of age (16,18). In both
humans with type 2 diabetes (12) and rodents with high
expression rates of human IAPP, there is increased -cell
apoptosis characterized by endoplasmic reticulum (ER)
stress (19,20). -Cell loss, therefore, in type 2 diabetes has
many parallels with that in neurodegenerative diseases
also characterized by protein misfolding (21). In Alzhei-
mer’s and Parkinson’s disease, for example, neuronal cell
loss is characterized by increased ER stress–induced
apoptosis accompanied by formation of toxic oligomers of
locally expressed amyloidogenic proteins (22). Collec-
tively these diseases have been referred to as protein
misfolding diseases.
In occasional families, protein misfolding diseases can be
attributed to a mutation that increases the propensity of the
respective amyloidogenic protein to aggregate (23). In most
cases, however, the basis for protein misfolding is not the
result of a mutant amyloidogenic protein, but rather a con-
sequence of an imbalance between the delivery of nascent
protein to the ER and the capacity of the ER to fold, trafﬁc,
and process the protein (22). Support for the concept of a
threshold of expression rate above which ER fails to ade-
quately process IAPP is provided by human IAPP transgenic
rodent models recently reviewed elsewhere (24). Given the
complexity of ER function (including calcium homeostasis,
chaperone proteins, glycosylation, clearance of misfolded
proteins), it is likely that this threshold varies widely between
individuals within the population, perhaps contributing to the
genetic variance in predisposition to type 2 diabetes. It is of
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(25).
It is therefore plausible that the link between the increased
risk for type 2 diabetes in obesity is mediated through an
imbalance between the delivery of nascent IAPP to the ER
and the capacity of the ER to fold, trafﬁc, and process this
amyloidogenic protein in vulnerable individuals. It is not
possible to address this hypothesis experimentally in hu-
mans. To gain insight into this postulate, we undertook
studies in wild-type (WT) Sprague-Dawley rats and Sprague-
Dawley rats transgenic for human IAPP (HIP rats) on a
high-fat diet (HFD). We hypothesized that WT rats would
adapt to an HFD to remain nondiabetic, whereas HIP rats
would fail to adapt and would develop diabetes. This hypoth-
esis was afﬁrmed, permitting us to further establish the
molecular, pathological, and physiological basis of successful
versus failed adaptation to an HFD in vivo as well as at the
level of the pancreas.
RESEARCH DESIGN AND METHODS
Animal housing, diet administration, and surgical procedures. A total of
54 Sprague-Dawley rats (WT; n  25) and rats expressing human IAPP (HIP
rats; n  29) were used. The generation of the human IAPP transgenic rats has
been described in detail previously (16). Rats were bred and housed individ-
ually throughout the study at the University of California, Los Angeles (UCLA)
animal housing facility and subjected to a standard 12-h light-dark cycle. The
UCLA Institutional Animal Care and Use Committee approved all surgical and
experimental procedures. At 2 months of age, WT and HIP rats were randomly
assigned to either an HFD (60% fat, 20% protein, and 20% carbohydrates;
Research Diets, New Brunswick, NJ) or a control regular chow diet (10% fat,
20% protein, and 70% carbohydrates; Research Diets) and fed ad libitum for 10
weeks. After 10 weeks of either diet, treatment animals were anesthetized
with isoﬂurane (2.5%) by inhalation until effect, and indwelling catheters were
then inserted into the right internal jugular vein and left carotid artery for
subsequent in vivo metabolic studies as previously described (26). All
catheters were ﬁlled with 100 U/ml heparin/saline solution, exteriorized to the
back of the neck, and encased in the infusion harness (Instech, Plymouth
Meeting, PA). After surgery, all rats maintained preoperative body weight and
had normal food intake and mean hematocrit (40%).
Hyperglycemic clamp and arginine bolus injection. To assess glucose and
arginine-stimulated insulin secretion, HIP (n  10), HIP  HFD (n  9), WT
(n  6), and WT  HFD (n  12) rats underwent a hyperglycemic clamp
followed by an arginine bolus injection as previously described (18). In brief,
after a 30-min equilibration period, plasma samples were taken for measure-
ments of fasting glucose, insulin, C-peptide, and free fatty acids. Thereafter,
animals received an intravenous glucose bolus (375 mg/kg) followed by a
variable 50% (wt/vol) glucose infusion to clamp arterial glucose at 250 mg/dl
(0–70 min). At 60 min, rats received a bolus injection of L-arginine solution (1
mmol/kg; Sigma, St. Louis, MO). Arterial blood samples (50 l) were taken at
baseline (30 and 0 min), at 1 and 5 min, and every 15 min thereafter during
the clamp for immediate determination of plasma glucose and subsequent
analysis for insulin and C-peptide.
Hyperinsulinemic-euglycemic clamp 
3H-glucose infusion. To assess
insulin sensitivity and glucose turnover, HIP (n  7), HIP  HFD (n  7), WT
(n  6), and WT  HFD (n  7) rats underwent a hyperinsulinemic-
euglycemic clamp with concomitant infusion of [3-
3H]glucose to assess
glucose turnover as previously described (18). Rats received primed (3 Ci)
continuous (0.05 Ci/min) infusion of [3-
3H]glucose (Perkin Elmer, Boston,
MA) for a 90-min basal period increased to 0.2 Ci/min for 120 min throughout
the hyperinsulinemic-euglycemic clamp. Plasma glucose was determined
every 10 min, and additional blood samples (150 l) for determination of
tracer-speciﬁc activity at fasting were drawn from 40 to 0 min and during
insulin infusion from 120 to 150 min.
Pancreas morphology. At the end of the hyperinsulinemic-euglycemic
clamp, rats were euthanized and the pancreas was then rapidly removed and
ﬁxed in 4% paraformaldehyde overnight at 4°C. Parafﬁn-embedded pancreatic
sections were stained ﬁrst for hematoxylin and eosin, insulin (guinea pig
anti-insulin, 1:100; Zymed, Carlsbad, CA). The -cell mass was measured by
quantifying the pancreatic cross-sectional area positive for insulin and multi-
plying this by the pancreatic weight. -Cell size was determined as a mean
distance between neighboring insulin-positive nuclei in 10 representative
islets per animal. -Cell nuclear diameter was determined as a mean (of 180
measurements per nucleus) nuclear diameter in insulin-positive nuclei in 10
representative islets per animal. Sections were also costained by immunoﬂu-
orescence for insulin (guinea pig anti-insulin, 1:100; Zymed) and terminal
deoxynucleotidyl transferase biotin-dUTP nick-end labeling (TUNEL method;
Roche Diagnostics, Mannheim, Germany) for quantiﬁcation of -cell apoptosis
and insulin (guinea pig anti-insulin, 1:100; Zymed) and Ki-67 (mouse anti–Ki-
67, 1:50; Dako, Carpinteria, CA) for determination of -cell replication.
Additional sections were costained by immunoﬂuorescence for insulin
(guinea pig anti-insulin, 1:100; Zymed) and anti-C/EBP homologous protein
(CHOP) (rabbit ant-CHOP; Santa Cruz Biotechnology) as previously described
in detail (19,20). All islets per pancreatic section (100 islets) were examined
in detail at 200 magniﬁcation (20 objective, 10 ocular) for the total
number of TUNEL, Ki-67, and CHOP-positive -cells. The frequency of
TUNEL, Ki-67, and CHOP expression in each animal was presented as total
number of stained -cells per total number of islets. Fluorescent slides were
analyzed and imaged using a Leica DM600 microscope (Leica Microsystems,
Wetzlar, Germany), and images were acquired using OpenLab software
(Improvision) and analyzed using ImagePro Plus software.
Islet isolation and Western blotting. To obtain rat islets, HIP (n  4), HIP 
HFD (n  4), WT (n  3), and WT  HFD (n  3) rats were euthanized, and
islets were isolated as previously described (19). For Western blotting
experiments, islets were washed with ice-cold PBS and lysed in 2 Laemmli
sample buffer immediately following the isolation procedure. Proteins (50
g/lane) were separated on a 4% to 12% Bis-Tris NuPAGE gel and transferred
to polyvinylidine ﬂuoride membranes (Bio-Rad). Membranes were blocked
with 5% nonfat dry milk in TBS/0.1% Tween-20 and incubated overnight at 4°C
with CHOP (1:500; Santa Cruz Biotechnology), anti-P-PERK (1:2,000; Cell
Signaling Technology, Beverly, MA), anti-GRP78 (1:10,000; Stressgen, Victoria,
BC, Canada), anti-hIAPP (1:6,000, 25–37 aa; Peninsula Laboratories, San
Carlos, CA), anti-insulin (1:100; Zymed), and anti-GAPDH (1:8,000; Cell
Signaling Technologies). Membranes were washed with TBS/0.1% Tween-20
and incubated with horseradish peroxidase–conjugated secondary antibodies
(1:3,000; Jackson Laboratories, Bar Harbor, ME) for 1 h. After washes,
proteins were visualized using enhanced chemiluminescence (Bio-Rad) and
protein expression levels were quantiﬁed using UN-SCAN-IT software (Silk
Scientiﬁc, Orem, UT).
Analytical procedures. Plasma glucose concentrations were measured by
the glucose oxidase method (Beckman Glucose Analyzer 2; Beckman, Fuller-
ton, CA). Plasma insulin and C-peptide levels were measured using ELISA
assay (Alpco Diagnostics, Salem, NH). Plasma free fatty acid levels were
measured using in vitro standard enzymatic colorimetric methods (WAKO
Chemicals, Richmond, VA). Plasma glucose speciﬁc activity, hepatic glucose
production, and glucose disposal were calculated as previously described in
detail (18).
Statistical analysis was performed using ANOVA analysis with Fisher’s post
hoc where appropriate. Regression analysis was performed using Statistica,
Version 6 (Statsoft, Tulsa, OK). Data in graphs and tables are presented as
means 	 SEM. Findings were assumed statistically signiﬁcant at P 
 0.05.
RESULTS
Development of diet-induced diabetes in HIP rats on
an HFD. Food intake, body weight, and plasma free fatty
acid levels increased comparably in WT and HIP rats on an
HFD (Fig. 1B and C; Table 1). The fasting plasma glucose
concentrations in HIP and WT rats were comparable at the
beginning of the study (P  0.85 between groups). On a
regular chow diet, fasting plasma glucose values remained
unchanged in the WT rats but increased to the impaired
fasting glucose concentration range in the HIP rats, con-
sistent with prior studies over the same age range (16,18).
On the HFD, there was a modest increase in blood glucose
in WT rats (110 	 3 versus 98 	 2 mg/dl; P  nonsigniﬁ-
cant for WT  HFD versus WT; Fig. 1A), but in contrast,
HIP  HFD rats developed diabetes (178 	 20 mg/dl; P 

0.0001 versus all other groups; Fig. 1A). Although there
was no relation between change in either body weight or
food intake and the fasting blood glucose concentration in
WT rats, both food intake (r  0.9, P 
 0.01) and increase
in body weight (r  0.9, P 
 0.01) during the 10-week
study predicted the subsequent fasting blood glucose
concentrations in HIP rats (Fig. 1D and E).
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in HIP rats. The HFD provoked a 46% increase in -cell
mass in WT rats (13 	 2 versus 19 	 2 mg, WT versus
WT  HFD; P 
 0.05), but no change of -cell mass in
HIP rats (12 	 1 versus 13 	 2 mg, HIP versus HIPHFD;
P  nonsigniﬁcant; Fig. 2A and B). The increase in -cell
mass in WT rats on an HFD was the result of -cell
hyperplasia rather than hypertrophy because -cell size
and nuclear diameter were unchanged (Fig. 2D and E).
-Cell apoptosis was increased almost 13-fold (0.04 	
0.006 versus 0.003 	 0.001 cells/islet; Fig. 3A and C, P 

0.001) in HIP versus WT rats on a regular diet, but this was
partially offset by a sixfold increase in -cell replication
(0.018 	 0.003 versus 0.003 	 0.003 cells/islet; Fig. 3B and
D). Although there was no increase (P  0.22) in -cell
apoptosis in WT rats on an HFD, -cell apoptosis in-
creased still further in HIP rats on the HFD (Fig. 3A and C,
P 
 0.0001, 34-fold versus WT rats). In contrast, there was
no further increase in -cell replication in HIP rats on the
HFD (Fig. 3B and D).
Unfolded protein response and ER stress and high-fat
feeding in WT versus HIP rats. To further elucidate the
underlying mechanism by which an HFD led to increased
-cell apoptosis in the HIP rats but not the WT rats, we next
investigated the unfolded protein response (P-PERK and
GRP-78) and ER stress by examining the protein expression
FIG. 1. Development of diet-induced diabetes in HIP rats on an HFD. Fasting plasma glucose (A), body weight (B), and mean daily food intake
(C) during 10-week treatment with 60% high fat (HFD) or regular chow diet in WT (n  19) and HIP rats (n  21). The relationship between the
change in body weight (D) and daily caloric food intake (E) versus fasting glucose levels in HIP rats (solid line) and WT rats (broken line) during
10-week treatment with 60% HFD or regular chow diet. F: The relation between the mean daily caloric food intake and change in body weight in
individual WT rats (broken line) and HIP rats (solid line). Data are means  SE. *P < 0.001 for HIP  HFD versus all groups; ‡P < 0.001 for
regular chow versus HFD. E, WT; ‚,W T HFD; F, HIP; Œ, HIP  HFD.
TABLE 1
Metabolic characteristics of HIP and WT rats after 10 weeks on an HFD or regular chow diet
WT WT  HFD HIP HIP  HFD
n 61 3 1 01 1
Weight (g) 571 	 27 725 	 30* 541 	 15 705 	 30*
Fasting glucose (mg/dl) 98 	 2 110 	 3 121 	 3 178 	 20†
Fasting insulin (pmol/l) 299 	 57 610 	 80* 179 	 28 518 	 113*
Fasting C-peptide (ng/ml) 1.9 	 0.2 3.1 	 0.5*‡ 1.3 	 0.2 1.8 	 0.2
Fasting free fatty acids (mmol/l) 0.4 	 0.1 1.1 	 0.4 0.5 	 0.1 0.8 	 0.2
Data are expressed as means 	 SEM. *P 
 0.05 for HFD versus regular chow. †P 
 0.05 for HIP  HFD versus all other groups. ‡P 
 0.05
for WT  HFD versus all groups.
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WT rats, the HFD increased both PERK phosphorylation and
GRP78 expression in relation to the primary ER client
protein insulin (Fig. 4A–C). In HIP rats, P-PERK and GRP78
expression were already increased on a regular chow diet in
comparison to WT rats in relation to insulin expression. In
HIP rats, however, neither P-PERK nor GRP78 expression
were further increased in response to the HFD (Fig. 4B and
D) despite the further increased expression of both insulin
and IAPP, so the protective unfolded protein response was
not further increased in the HFD-fed rats despite this marked
increased ER load. Nuclear CHOP expression was 13-fold
increased in HIP versus WT rats on a regular diet (0.049 	
0.011 versus 0.0037 	 0.002 -cells/islet, P 
 0.01; Fig. 4D–E)
and was increased further in HIP, but not WT, rats with an
HFD (0.049 	 0.011 versus 0.09 	 0.01 -cells/islet, P 
 0.01;
Fig. 4D and E). There was a positive correlation between the
frequency of -cell nuclear CHOP and -cell apoptosis (r 
0.6, P 
 0.001; Fig. 4F). Western blot analysis of protein
lysates from isolated islets conﬁrmed the immunohisto-
chemically detected increased CHOP protein expression in
HIP rats on a regular diet increased further on the HFD (Fig.
4A). These data reveal that an HFD exacerbated ER stress–
induced apoptosis in the HIP rat, but did not induce ER stress
in WT rats, implying that the propensity of human IAPP to
form toxic oligomers is an important link between an HFD
and ER stress–induced -cell apoptosis.
HIP rats fail to adaptively increase fasting, glucose-
stimulated, and arginine-stimulated insulin secretion
in response to HFD and have impaired hepatic insulin
clearance. In the fasting state, insulin secretion was im-
paired in HIP rats on an HFD, as illustrated by failure to
increase C-peptide concentrations despite hyperglycemia
(Fig. 5A, D, and G). In contrast, C-peptide concentrations
increased by 1.6-fold in WT rats on an HFD (1.9 	 0.2 versus
3.1 	 0.5 ng/ml, P 
 0.05; Fig. 5A, D, and G) in response to an
HFD. In contrast, although insulin secretion was impaired in
HIP rats in the fasting state (evaluated by C-peptide concen-
trations), systemic insulin concentrations were comparable
to those in WT rats (Table 1), indicating that hepatic insulin
clearance of endogenously secreted insulin was decreased in
HIP rats on a chow diet or HFD. To evaluate glucose-
mediated insulin secretion under comparable condi-
tions, we performed hyperglycemic clamp studies in
which, by design, plasma glucose levels were main-
tained at 265 	 10 mg/dl (supplemental Fig. 1, available
in an online appendix at http://diabetes.diabetesjournals.org/
cgi/content/full/db08-1464). In response to HFD, in WT
rats, the ﬁrst-phase insulin response to glucose was in-
creased by 1.7-fold (966 	 90 versus 1,677 	 108 pmol/l,
P 
 0.01, WT versus WT  HFD; Fig. 5B, E, and H) and the
second phase by twofold (705 	 33 versus 1,462 	 116
pmol/l, P 
 0.01, WT versus WTHFD; supplemental Fig.
1, available in the online appendix). In contrast, in HIP
rats, there was a markedly blunted ﬁrst- and second-phase
response to hyperglycemia and no increment with an HFD
(Fig. 5B, E, and H). Likewise, although there was a 1.5-fold
increase in arginine-stimulated insulin release in WT rats
in response to an HFD, there was no increase in arginine-
induced insulin secretion at the same glucose concentra-
tion in the HIP rat on a regular diet or HFD (Fig. 5C, F, and
I). Consistent with these ﬁndings, we observed a positive
correlation between -cell mass and fasting C-peptide (r 
0.5, P 
 0.01; Fig. 5D and G), ﬁrst-phase insulin response
to glucose (r  0.4, P 
 0.01; Fig. 5E and H), and
ﬁrst-phase insulin response to arginine (r  0.5, P 
 0.01;
Fig. 5F and I).
HIP rats on an HFD exhibit increased fasting and
insulin-stimulated hepatic glucose production. To fur-
ther elucidate the relation between hepatic and extrahe-
patic insulin sensitivity and -cell failure in HIP rats
exposed to an HFD, we undertook hyperinsulinemic-
A BC
DE
FIG. 2. Compensatory increase in -cell mass in response to an HFD is absent in HIP rats. A: Typical islets from wild-type (WT) and HIP rats
stained for insulin and hematoxylin after 10 weeks of 60% high-fat (HFD) or regular chow diet. Quantiﬁcation of -cell mass (B), mean islet
number per section (C), mean -cell size (D), and -cell nuclear diameter (E) after 10 weeks of 60% HFD or regular chow diet in WT (n  19)
and HIP rats (n  21). Data are means  SE. *P < 0.05; **P < 0.01. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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By design, plasma glucose and insulin concentrations
were comparable during the hyperinsulinemic-euglycemic
clamps in HIP and WT rats on a regular chow diet or HFD
(Fig. 6A). Whole-body insulin sensitivity, assessed by the
mean glucose infusion rates during the hyperinsulinemic
clamp, was comparably decreased by HFD in HIP and WT
rats (Fig. 6B). The isotope dilution technique revealed that
fasting hyperglycemia in the HIP  HFD group was
attributed to a twofold increase in fasting hepatic glucose
production (Fig. 6C, P 
 0.05 versus all other groups). In
HIP rats, there was hepatic insulin resistance (impaired
suppression of hepatic glucose release during the clamp)
(Fig. 6C). Isotopically measured insulin-stimulated glu-
cose uptake was comparably decreased by HFD in both
HIP and WT rats (Fig. 6D). An HFD had its primary
effect on insulin sensitivity by inducing extrahepatic
insulin resistance, whereas the HIP rat has a selective
defect in hepatic insulin sensitivity independent of the
HFD.
The interaction between insulin sensitivity and suc-
cessful versus failed -cell adaptation. In summary, WT
and HIP rats provided either a regular chow diet or HFD for
10 weeks had an average daily food intake that varied from
100 to 200 Kcal/day. Weight gain and subsequent insulin
resistance was proportionate to average food intake, which
was comparable in WT and HIP rats. In WT rats, -cell mass
and function successfully adapted to insulin resistance. The
adaptive increase in -cell mass was accomplished by in-
creased -cell replication in the absence of any increase in
-cell apoptosis (Fig. 7B, D, and F). In contrast, in HIP rats,
neither -cell function nor mass adaptively increased to the
increased demand imposed by an HFD (Fig. 7E). In HIP rats,
increasing insulin resistance provoked increased -cell apop-
tosis (Fig. 7A) but with no effective increase in -cell repli-
cation (Fig. 7B).
DISCUSSION
An HFD leads to obesity and insulin resistance (1) that in
most individuals is compensated by increased -cell mass
FIG. 3. HFD leads to increased -cell apoptosis in HIP rats and increased -cell replication in wild-type rats. A and B: Examples of islets stained
for insulin (green) and apoptosis marker TUNEL (red)( A) and islets stained for insulin and replication marker Ki-67 (red) and nuclear stain
DAPI (blue)( B) imaged at 200. C and D: Quantiﬁed frequency of -cell apoptosis and replication after 10 weeks of 60% HFD or regular chow
diet in WT (n  19) and HIP rats (n  21). Data are means  SE. *P < 0.05; **P < 0.01. Note that the frequency of TUNEL- and Ki67-positive
cells in islets shown in A and B are higher than the mean to reveal the ﬁdelity of the immunostaining rather than representative of the mean. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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diabetes, hyperglycemia occurs as a consequence of im-
paired insulin secretion in response to insulin resistance
(27,28) with characteristic islet pathology including a
deﬁcit in -cell mass (12,13), islet amyloid derived from
IAPP, and ER stress–induced -cell apoptosis (20,29). We
sought to gain insights into the mechanisms underlying the
appropriate adaptive versus maladaptive -cell response
to HFD-induced insulin resistance.
In humans, prospective measurements of the adaptive
changes in -cell mass and corresponding changes in
insulin secretion and insulin resistance in response to
obesity are unavailable because longitudinal studies of
pancreatic morphology cannot be performed. Cross-
sectional studies of islet morphology in humans report a
50% increase in -cell mass in obese individuals compared
with their lean counterparts (12). Similarly, cross-sectional
studies that examined changes in insulin secretion and
insulin sensitivity in obesity report an 1.5- to 3-fold
increase in fasting and meal-stimulated insulin secretion
(6,7,28) and an 50% decrease in insulin sensitivity
(28,30). We report that 10 weeks of high-fat feeding
initiated at 2 months of age in the Sprague-Dawley rat
induced a 46% increase in -cell mass and a 1.5- to 2-fold
increase in fasting and glucose-stimulated insulin secre-
tion in response to a 50% decline in whole body insulin
sensitivity. The adaptive changes in the WT rat on an HFD
therefore recapitulate those observed in nondiabetic
obese humans. We report for the ﬁrst time in the same
animals that the adaptive changes in insulin secretion in
WT  HFD animals is closely related to the adaptive
increase in -cell mass.
In contrast to WT rats, HIP rats failed to adaptively
increase -cell mass and insulin secretion in response to
HFD-induced insulin resistance. -Cell replication was
increased in HIP rats compared with WT rats at baseline,
but this increased -cell replication was offset by in-
creased -cell apoptosis so that -cell mass was compa-
rable in WT and HIP rats. -Cell replication failed to
increase further in HIP rats on an HFD despite a marked
further increase in -cell apoptosis, consistent with prior
studies showing that newly forming -cells have in-
creased vulnerability to IAPP-induced apoptosis (31). A
primary goal of the present studies was to gain insights
into the successful versus failed adaptation to high
fat–induced obesity. Having noted that failure to expand
FIG. 4. HFD leads to increased ER stress in HIP rats. A: Immunoblot analysis of P-PERK, GRP-78, insulin, IAPP, and CHOP in protein lysates from
islets isolated after 10 weeks of a 60% HFD or regular chow diet in WT (n  6) and HIP rats (n  8). B and C: Quantiﬁcation of P-PERK and
GRP-78 expression normalized to insulin expression. D: Representative examples of islets stained by immunoﬂuorescence for insulin (green), ER
stress marker CHOP (red), and nuclear stain DAPI (blue) imaged at 200. E and F: Quantiﬁed frequency of nuclear CHOP expression per islet
and (E) a relation between the frequency of -cell CHOP versus TUNEL expression after 10 weeks of 60% HFD or regular chow diet (F)i nW T
(n  19) and HIP rats (n  21) rats. Data are means  SE. *P < 0.05; **P < 0.05. Note that the frequency of CHOP-positive cells in islets shown
in D are higher than the mean to reveal the ﬁdelity of the immunostaining rather than representative of the mean. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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stress–induced -cell apoptosis, we turned our attention
to the role of the ER in the successful versus failed
adaptation to an HFD.
The ER in the -cell is well developed to permit synthe-
sis, folding, processing, and export of the primary client
secretory proteins, insulin, and IAPP. The unfolded pro-
tein response (UPR) is an important adaptive regulatory
mechanism that seeks to balance the rate of delivery of
nascent proteins into the ER with the capacity of the ER to
fold and export these proteins (32). The UPR accom-
plishes this both by constraining the rate of protein
synthesis as well as enhancing the capacity of this system,
for example, by increasing the ER chaperone protein BIP
that binds to all nascent ER proteins as they are inserted
into the ER (33). Evidence that the UPR was intact in WT
rats is provided by increased PERK phosphorylation and
GRP78 expression in relation to the primary ER client
proteins insulin and IAPP. In contrast, although PERK
phosphorylation and GRP78 expression were increased in
HIP rats on a regular chow diet in comparison to WT rats,
in relation to insulin expression, the UPR was not further
increased in response to the HFD. It is therefore plausible
that high expression rates of oligomeric proteins (such as
human IAPP) may lead to ER stress, in part attributable to
the failure of an adequate unfolded protein response.
Consistent with action of CHOP to mediate ER stress–
induced apoptosis, we observed a similar twofold in-
crease in -cell apoptosis in response to an HFD in HIP,
but not in WT, rats. There was a positive correlation
between nuclear CHOP and -cell apoptosis (r  0.6,
P  0.0001; Fig. 4F).
To underscore the postulate that -cell ER stress–
induced apoptosis is related to the extent of insulin
resistance in those genetically vulnerable, the frequency of
-cell apoptosis was positively related to the degree of
insulin resistance in HIP rats (P 
 0.05), but not WT rats
(P  0.6). The close parallels in the islet pathology
FIG. 5. HIP rats fail to adaptively increase fasting, glucose-stimulated, and arginine-stimulated insulin secretion in response to an HFD. Mean
fasting C-peptide levels (A), ﬁrst-phase glucose (B), and arginine-stimulated insulin secretion (C). D–I: Regression analysis of relations between
changes in -cell mass and fasting, glucose-stimulated, and arginine-stimulated insulin secretion in WT (n  18) and HIP rats (n  19) after
10-week treatment with 60% HFD or regular chow diet. Data are means  SE. *P < 0.05; **P < 0.01.
ROLE OF IAPP-INDUCED -CELL ENDOPLASMIC RETICULUM STRESS
912 DIABETES, VOL. 58, APRIL 2009between the HFD-fed HIP rat and obese humans with type
2 diabetes (-cell deﬁcit resulting from ER stress–induced
-cell apoptosis) are consistent with the postulate that
humans genetically at risk of type 2 diabetes, like the HIP
rat, have a marginal capacity for ER to trafﬁc IAPP that is
readily overcome by induction of insulin resistance. In
contrast, humans who are not genetically vulnerable to
type 2 diabetes are capable of adapting to insulin resis-
tance and so presumably have a much higher threshold for
expression and trafﬁcking of IAPP.
We note that both WT and HIP rats developed compa-
rable insulin resistance in extrahepatic tissues on an HFD.
Hepatic insulin resistance in response to high-fat feeding
was more prominent in the HIP rats. We previously
reported that the loss of -cell mass in the HIP rat leads to
hepatic insulin resistance (18). One possible explanation
for this ﬁnding is that the impaired pulsatile delivery of
insulin to the liver leads to hepatic insulin resistance. In
health, insulin is secreted in discrete insulin secretory
bursts that present the liver with an insulin concentration
proﬁle that oscillates with an amplitude of 1,000 pmol/l
in the fasting state and up to 5,000 pmol/l after meal
ingestion (34,35), an observation recently conﬁrmed in
vivo in rats (26). The magnitude of these bursts is substan-
tially decreased in patients with type 2 diabetes (36) and in
animal models of reduced -cell mass (37,38), including
the HIP rat (A.V.P. and P.C.B., unpublished observations).
It has been proposed that pulsatile mode of insulin deliv-
ery to liver increases hepatic insulin sensitivity (39,40),
possibly by avoiding insulin receptor downregulation
and/or sustained activation of AKT with attendant feed-
back inhibition of IRS-2 (41). We postulate that the more
prominent hepatic insulin resistance in the HIP rat on an
HFD (and in obese patients with type 2 diabetes) may
relate at least in part to the decline in -cell mass leading
to an abnormal pattern of insulin delivery to the liver.
We also document a decrease in hepatic insulin clear-
ance in HIP rats fed an HFD. Although fasting insulin
levels in HIP rats increased almost threefold in response to
an HFD, C-peptide levels remained relatively unchanged
(Table 1). Thus, in the HIP rat, the C-peptide–to–insulin
molar ratio, a measure of insulin clearance, was reduced
by 40% in high fat–fed HIP rats. We have previously
reported that the amplitude of insulin pulses directed to
FIG. 6. HIP rats on HFD exhibit increased fasting and insulin-stimulated hepatic glucose production. A: Fasting (30 and 0 min) and
hyperinsulinemic-euglycemic clamp glucose concentrations. B: Mean glucose infusion rates required to maintain euglycemia during the hyperinsuline-
mic clamp. C and D: Mean rates of hepatic glucose production (C) and glucose disposal (D) at fasting and during the ﬁnal 30 min of the
hyperinsulinemic-euglycemic clamp in WT (n  13) and HIP rats (n  14) after 10-week treatment with 60% HFD or regular chow. Data are means 
SE. *P < 0.05 for HIP versus WT; **P < 0.05 for HIP  HFD versus all groups; ‡P < 0.05 for HFD versus chow.
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humans (42). Consistent with this hypothesis, hepatic
insulin clearance is decreased in animal models of reduced
-cell mass/insulin pulse mass as well as in humans with
diabetes (37,38,43,44). Because hepatic insulin extraction
depends on the amplitude of insulin pulses presented to
the liver (42), deﬁcits in insulin secretion, at least in the
fasting state, would be largely offset in the systemic
circulation by decreased hepatic insulin clearance.
In summary, an HFD induced a comparable increase in
expression of IAPP and induction of UPR in -cells
irrespective of amyloidogenic potential of expressed IAPP.
However, despite the induction of the UPR, an HFD still
led to -cell ER stress–mediated apoptosis in the HIP but
not WT rats with islet pathology that recapitulates that in
humans with type 2 diabetes. Speciﬁcally, the -cell mass
was deﬁcient in the high fat–fed HIP rats, because the
increased -cell apoptosis prevented an appropriate adap-
FIG. 7. HFD-induced insulin resistance correlates with the increase in -cell apoptosis in HIP rats and increase in -cell replication in WT rats.
Regression analysis of relations among the -cell apoptosis, -cell replication, and -cell mass versus hyperinsulinemic-euglycemic clamp
determined insulin sensitivity in WT rats (n  13) (B, D, and F) and HIP rats (n  14) (A, C, and E) after 10-week treatment with 60% HFD or
regular chow.
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stress and a deﬁcit in -cell mass in high fat–fed HIP rats
were impaired insulin secretion and hyperglycemia. This
-cell failure led to a further exacerbation of the HFD-
induced insulin resistance in the HIP rat.
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